HLS Share Price Performance
CA$4.79
1.00 (26.39%)
25.4% undervalued intrinsic discount
CA$6.42
Fair Value
Price CA$4.79
AnalystConsensusTarget CA$6.42
AnalystHighTarget CA$12.01
AnalystLowTarget CA$4.76
Fair ValueCA$6.42
Share Pricen/a
HLS Therapeutics Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
HLS Community Narratives
AN
Fair Value CA$6.42 25.4% undervalued intrinsic discount
Canadian Regulatory Approvals Will Foster A Vibrant Cardiovascular Market
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value CA$12.01 60.1% undervalued intrinsic discount
Aging Populations And Digital Patient Care Will Boost Vascepa Demand
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value CA$4.76 0.6% overvalued intrinsic discount
Price Controls And Generics Will Erode Future Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Price Controls And Generics Will Erode Future Margins
Key Takeaways Upcoming patent expiries and growing generic competition threaten HLS's ability to sustain premium pricing, top-line sales, and long-term financial stability. Overreliance on a limited product range and lack of early-stage pipeline heighten the risk of volatile earnings and revenue contraction.Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CA$4.76
0.6% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
5.86% p.a.
Profit Margin
6.79%
Future PE
26.64x
Price in 2029
CA$5.46
Aging Populations And Digital Patient Care Will Boost Vascepa Demand
Key Takeaways Expansion of the cardiovascular portfolio and operational efficiencies could significantly boost both margins and long-term earnings, surpassing current market expectations. Strategic financial discipline and demographic tailwinds position the company to pursue new growth avenues and sustain high revenue potential in its specialty portfolio.Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CA$12.01
60.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
8.48% p.a.
Profit Margin
3.08%
Future PE
137.54x
Price in 2028
CA$13.99
Canadian Regulatory Approvals Will Foster A Vibrant Cardiovascular Market
Key Takeaways New product launches and expanded payer coverage are set to drive strong growth and improved profitability in the cardiovascular segment. Effective cost controls and enhanced financial flexibility support greater shareholder returns and long-term revenue stability.Read more
22
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CA$6.42
25.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
5.35% p.a.
Profit Margin
2.85%
Future PE
103.12x
Price in 2028
CA$7.59
Trending Discussion
Recently Updated Narratives
AN
HLS: Higher Rating Outlook Will Balance Execution Risks And Near Term Guidance
Fair Value: CA$4.76 0.6% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
HLS: Higher Projected Earnings Will Support Stronger Future Share Performance
Fair Value: CA$12.01 60.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
HLS: Ongoing Share Buybacks And Debt Reduction Will Drive Positive Momentum
Fair Value: CA$6.42 25.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
HLS Therapeutics Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.45
- 71.82%
- -25.28%
- 86.0%
About HLS
- Founded
- n/a
- Employees
- 92
- CEO
- WebsiteView website
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company’s lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds royalty interest in Takeda’s Obizur, which is a porcine recombinant Factor VIII for acquired Hemophilia A. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
